Advancing a class on top of statins
Investors & Media

Investor Overview

Gemphire is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for the treatment of dyslipidemia, a serious medical condition that increases the risk of life threatening cardiovascular disease. Dyslipidemia is generally characterized by an elevation of low-density lipoprotein cholesterol (LDL-C), or bad cholesterol, triglycerides, or fat in the blood, or both... More >>

NASDAQ | GEMP (Common Stock)

$10.66

 0.19 (1.75%)

High$10.98
Low$10.55
Volume29,343
Market Cap$112,962,293

04/27/17  4:00 p.m. ET

Data provided by Nasdaq. Minimum 15 minutes delayed.
Stock chart for: GEMP.O.  Currently trading at $10.66 with a 52 week high of $13.98 and a 52 week low of $7.25.

Gemphire Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

03/29/17

Read More

Gemphire Therapeutics Announces Presentation at ACC Meeting of Phase 2 Clinical Trial Investigating Effect of Gemcabene on Insulin Sensitization

03/21/17

Read More

Gemphire to Present at the Oppenheimer Annual Healthcare Conference and the H.C. Wainwright NASH Investor Event

03/16/17

Read More


There are currently no events scheduled.